AbCellera Biologics EBITDA Margin 2019-2025 | ABCL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

AbCellera Biologics ebitda margin from 2019 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

AbCellera Biologics EBITDA Margin 2019-2025 | ABCL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

AbCellera Biologics ebitda margin from 2019 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.5B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$146.9B
Vertex Pharmaceuticals (VRTX)	$100.7B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.1B
GSK (GSK)	$80.2B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.8B
Argenex SE (ARGX)	$40B
BioNTech SE (BNTX)	$27.3B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$21.2B
Biogen (BIIB)	$20.3B
Incyte (INCY)	$17B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$11B
Moderna (MRNA)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.6B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B
Halozyme Therapeutics (HALO)	$7.9B